JPWO2021242848A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021242848A5
JPWO2021242848A5 JP2022572657A JP2022572657A JPWO2021242848A5 JP WO2021242848 A5 JPWO2021242848 A5 JP WO2021242848A5 JP 2022572657 A JP2022572657 A JP 2022572657A JP 2022572657 A JP2022572657 A JP 2022572657A JP WO2021242848 A5 JPWO2021242848 A5 JP WO2021242848A5
Authority
JP
Japan
Prior art keywords
dota
seq
lys
binding fragment
bispecific antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527385A (ja
JP2023527385A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034230 external-priority patent/WO2021242848A1/en
Publication of JP2023527385A publication Critical patent/JP2023527385A/ja
Publication of JPWO2021242848A5 publication Critical patent/JPWO2021242848A5/ja
Publication of JP2023527385A5 publication Critical patent/JP2023527385A5/ja
Pending legal-status Critical Current

Links

JP2022572657A 2020-05-27 2021-05-26 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用 Pending JP2023527385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030591P 2020-05-27 2020-05-27
US63/030,591 2020-05-27
PCT/US2021/034230 WO2021242848A1 (en) 2020-05-27 2021-05-26 Anti-gd2 sada conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2023527385A JP2023527385A (ja) 2023-06-28
JPWO2021242848A5 true JPWO2021242848A5 (https=) 2024-06-03
JP2023527385A5 JP2023527385A5 (https=) 2024-06-03

Family

ID=78722708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572657A Pending JP2023527385A (ja) 2020-05-27 2021-05-26 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用

Country Status (7)

Country Link
US (1) US20230235087A1 (https=)
EP (1) EP4157293A4 (https=)
JP (1) JP2023527385A (https=)
CN (1) CN116194133A (https=)
AU (1) AU2021280272A1 (https=)
CA (1) CA3180445A1 (https=)
WO (1) WO2021242848A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583588B2 (en) * 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
EP4448565A1 (en) 2021-12-15 2024-10-23 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation
JP2024546804A (ja) * 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド Ｓａｄａ複合体を含む製剤
US20260021206A1 (en) * 2022-07-25 2026-01-22 Vironexis Biotherapeutics Inc. Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US11583588B2 (en) * 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
US11565005B2 (en) * 2017-07-06 2023-01-31 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
EP3765031A4 (en) * 2018-03-14 2022-03-23 Memorial Sloan Kettering Cancer Center ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF
AU2020225631A1 (en) * 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
EP3938400B1 (en) * 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体

Similar Documents

Publication Publication Date Title
Barbet et al. Pretargeting with the affinity enhancement system for radioimmunotherapy
Sharkey et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody
RU2420536C2 (ru) Пептидные производные эксендина-4
DE69231586T2 (de) Pharmazeutische anwendungen auf der basis von peptid-metall-ionen
Blankenberg Recent advances in the imaging of programmed cell death
US6241961B1 (en) Radioimmuno conjugates for use in human therapy and method for their preparation
CA2555666A1 (en) Therapeutic and diagnostic conjugates for use with multispecific antibodies
KR20080009682A (ko) 킬레이트제인 폴리(펩티드): 제조 방법과 용도
JPWO2021005125A5 (https=)
JPWO2021242848A5 (https=)
HUE032093T2 (en) An oxidized avidin with high residence time in treated tissues
Gruaz-Guyon et al. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy
EP0594739B1 (en) Cancer treatment
US5718882A (en) IKVAV peptide radiopharmaceutical applications
CA2302636C (en) Imaging methods and compositions
CA2723323A1 (en) Use of a radioactively labelled molecule specifically binding to ed-b fibronectin in a method of treatment of hodgkin lymphoma
Khaw Antibodies as delivery systems for diagnostic functions
Hiroshima et al. A case of primary sarcoma of the pulmonary artery
Hnatowich et al. Pharmacokinetics of the FO23C5 anti-CEA antibody fragment labelled with 99Tcm and 111In: a comparison in patients
JP7854076B2 (ja) 放射性医薬組成物及び方法
JP2024540169A (ja) がんを処置する方法
KR101201557B1 (ko) 상피세포 유래 암질환 표적 펩타이드 및 이의 의학적 용도
Sharkey et al. Anti-antibody enhancement of tumor imaging
Paganelli et al. Therapy trials in cancer patients using an improved 3-step pretargeting approach
Chopra 111 In-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N’, N”, N”’-tetraacetic acid (DOTA)-D-Tyr-D-Lys (HSG)-D-Glu-D-Lys (HSG)-NH2 (IMP-288)[[111 In]-IMP-288],”